IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
31 oct. 2024 08h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
22 oct. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies...
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
15 oct. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
30 sept. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
09 mai 2024 09h31 HE
|
Spherix Global Insights
Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape...
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
07 nov. 2023 10h41 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
ANVS MONDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
12 oct. 2021 13h38 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and...
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12 oct. 2021 12h15 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
05 oct. 2021 17h31 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and...
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
05 oct. 2021 11h35 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 05, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...